Drug Type Synthetic peptide |
Synonyms Valspodar (USAN/INN), PSC 833, PSC-833 + [5] |
Target |
Mechanism P-gp inhibitors(P-glycoprotein 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC63H111N11O12 |
InChIKeyYJDYDFNKCBANTM-QCWCSKBGSA-N |
CAS Registry121584-18-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Basophilic Leukemia | Phase 3 | US | 01 Nov 2000 | |
Acute Eosinophilic Leukemia | Phase 3 | US | 01 Nov 2000 | |
Childhood Acute Monoblastic Leukemia and Acute Monocytic Leukemia | Phase 3 | US | 01 Nov 2000 | |
untreated pediatric acute nonlymphocytic leukemia | Phase 3 | US | 01 Nov 2000 | |
Myelodysplastic Syndromes | Phase 3 | US | 01 Nov 2000 | |
Acute Erythroblastic Leukemia | Phase 3 | US | 01 Jan 1998 | |
Acute Megakaryoblastic Leukemia | Phase 3 | US | 01 Jan 1998 | |
Acute Myelomonocytic Leukemia | Phase 3 | US | 01 Jan 1998 | |
Adult Acute Monoblastic and Monocytic Leukemia | Phase 3 | US | 01 Jan 1998 | |
Adult acute myeloid leukemia with del(5q) | Phase 3 | US | 01 Jan 1998 |
Phase 3 | 302 | ADE (cytosine arabinoside (Ara-C), daunorubicin (D), and etoposide (E)) | igdzljqlyy(rvnfbtntis) = bnaycrmxun zhxfwlezgw (eopmccxhfz ) View more | Negative | 02 Sep 2010 | ||
igdzljqlyy(rvnfbtntis) = hlgyctlsxj zhxfwlezgw (eopmccxhfz ) View more |